title: Emerging therapeutic aspects in oncology.
abstract: Cancer remains a peculiarly stubborn disease to treat. Some forms of cancer have seen tremendous advances in the effectiveness of their treatments, whereas other forms have remained resistant to pharmacological control. This lack of hope for success is in part due to the types of drugs that are used in the clinic, and the targeted biological system being based purely on cellular growth rates. However, recent drugs designed to affect specific signalling pathways or proteins have been showing much success. Thanks to the ingenuity of pharmacologists in understanding and targeting these processes, there have been real improvements in treatment. Here we are presented with some of the research into such critical systems that have to be understood, so that they can be conquered. We will also look at the challenges facing cancer pharmacologists and what the field may present to us all in the future.
  
  
  BACKGROUND
  This article is part of a themed section on Emerging Therapeutic Aspects in Oncology. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue-8.
authors.forename: David J
authors.initials: DJ
authors.lastname: Macewan
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: TKI; biologics; chemotherapy; drug resistance; tumor
references.citation: Br J Pharmacol. 2013 Aug;169(8):1708-22
references.pmid: 23647573
references.citation: Can Med Assoc J. 1936 Jun;34(6):683-4
references.pmid: 20320291
references.citation: Br J Pharmacol. 2002 Feb;135(4):855-75
references.pmid: 11861313
references.citation: Br J Pharmacol. 2013 Aug;169(8):1723-44
references.pmid: 23638798
references.citation: Br J Pharmacol. 2013 Aug;169(8):1693-707
references.pmid: 23517124
references.citation: Br J Pharmacol. 2013 Aug;169(8):1672-92
references.pmid: 23425071
references.citation: Cancer Res. 2011 Jun 15;71(12):4117-29
references.pmid: 21505102
references.citation: Br J Pharmacol. 2013 Aug;169(8):1745-65
references.pmid: 23682925
references.citation: Br J Pharmacol. 2013 Aug;169(8):1652-71
references.pmid: 23714011